MEK Inhibitors in Neurofibromatosis Type 1: Latest Advances and Real-world Applications in NF1-PN Management-Copy

Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of near- and long-term clinical manifestations makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively impacts patients’ clinical outcomes and quality of life. These challenges necessitate an integrated, longitudinal management approach that encompasses the totality of the interprofessional, multidisciplinary team of clinicians in pediatric and adult care settings.

In this CEC Oncology recorded, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person’s lifespan; explore the integration of MEK inhibitors in the management of NF1-associated PNs in pediatric patients; and consider comprehensive interprofessional care plans that include disease monitoring, toxicity management, and individualizing disease treatment across the patient’s lifespan.

At the conclusion of this activity, learners will be able to better:

• Identify key characteristics of neurofibromatosis type 1 (NF1) clinical presentation and disease advancement across the lifespan, including genetic etiology and multisystem pathophysiology of NF1, that impact early and accurate diagnosis
• Integrate MEK inhibitors in the management of NF1-associated plexiform neurofibromas (PNs) in pediatric patients
• Develop comprehensive care plans that include disease monitoring, managing toxicities, and personalized treatment for patients with NF1 across the lifespan

This program is supported through independent educational grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.

Neuro-oncologists, general oncologists, general neurologists, pediatric oncologists, physician associates (PAs), nurse practitioners (NPs), and nurses 

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Hirbe reports the following financial relationships:

Advisory Board: Aadi Subsidiary, Inc.

Consultant: Aadi Subsidiary, Inc.; Alexion Pharmaceuticals, Inc.; AstraZeneca; and SpringWorks Therapeutics, Inc.

Grants: Tango

Other financial or material support: Boehringer Ingelheim

Dr. Armstrong reports the following financial relationships:

Advisory Board: Alexion Pharmaceuticals, Inc

Consultant: Alexion Pharmaceuticals, Inc. and SpringWorks Therapeutics, Inc.

Patient Advocates/Planners

Evan Neale reports no financial relationships to disclose

Sarah Neale reports no financial relationships to disclose

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Andrea Edwards, PA-C (Peer Reviewer)
David Modrak, PhD (Planning Committee)
Nichole Lainhart (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.